Imunon, Inc. is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies and DNA-based vaccines aimed at treating challenging diseases. The company's leading program, IMNN-001, is a DNA-based immunotherapy in Phase II clinical trials targeting localized ovarian cancer. Beyond this, Imunon advances several preclinical candidates, including a COVID-19 booster vaccine and therapies for viral infections like Lassa fever and cancers such as melanoma. Utilizing proprietary non-viral DNA technology platforms—TheraPlas and PlaCCine—Imunon harnesses genetic coding to stimulate targeted immune responses, addressing solid tumors and infectious agents effectively. Founded in 1982 and headquartered in Lawrenceville, New Jersey, Imunon operates at the intersection of immunology and genetic therapy, striving to bring new therapeutic options to patients facing difficult-to-treat conditions. The company's focused pipeline and technological platforms position it as a notable player in the biotechnology and healthcare sectors.